Browsing Tag
Type 1 diabetes
14 posts
Why the EMA review of PolTREG-T1D could influence autoimmune cell therapy development
PolTREG-T1D moves toward European Medicines Agency review. Discover how this TREG cell therapy could reshape treatment for autoimmune diseases.
FDA green light fast-tracks Diamyd Medical’s type 1 diabetes verdict by nine months
Diamyd Medical accelerates its Phase 3 type 1 diabetes trial after FDA alignment. Find out what the earlier data readout means for approval prospects.
NLS Pharmaceutics and Kadimastem merger gains BIRD Foundation boost for breakthrough Type 1 diabetes therapy
Discover how NLS Pharmaceutics and Kadimastem’s merger, backed by renewed BIRD Foundation funding, positions NewCelX to challenge global leaders in diabetes cell therapy.
vTv Therapeutics begins Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes patients
vTv Therapeutics has launched its Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes. Find out what this means for patients and investors today.
UK approves first-ever immunotherapy for type 1 diabetes — can teplizumab really delay onset by three years?
MHRA approves teplizumab, the UK’s first immunotherapy for type 1 diabetes, delaying onset by three years. See how it could reshape care pathways.
Stem cell-based diabetes therapies at ADA 2025 show promise in eliminating insulin use for type 1 patients
VX-880 and immune-shielded stem cell islets show strong promise in clinical trials at ADA 2025, offering new possibilities in type 1 diabetes treatment.
Smart insulin system improves glucose control for pregnant women with type 1 diabetes, according to ADA 2025 clinical trial findings
Smart insulin system shows improved glucose control in pregnancy with type 1 diabetes, per ADA 2025 trial; regulatory expansion expected. Read full details.
How are AI models and new clinical treatments reshaping diabetes care after the 2025 ADA conference?
ADA 2025 highlights AI diagnostics and breakthrough injectables in diabetes care, signaling early detection and superior glycemic control in clinical trials.
Game-changer for diabetes? Tandem’s Control-IQ+ automated insulin delivery system now available in the US
Tandem Diabetes Care launches Control-IQ+ automated insulin delivery for type 1 and type 2 diabetes, expanding access to advanced insulin automation in the U.S.
Lilly wraps up Sigilon Therapeutics acquisition to amplify Type 1 diabetes research
Eli Lilly and Company (Lilly) has formally announced the culmination of its $309.6 million takeover of biopharma trailblazer,…